Edition:
United States

InMed Pharmaceuticals Inc (IN.CD)

IN.CD on Canadian Securities Exchange

0.09CAD
28 Jul 2016
Change (% chg)

$0.00 (+6.25%)
Prev Close
$0.08
Open
$0.09
Day's High
$0.09
Day's Low
$0.08
Volume
32,957
Avg. Vol
114,983
52-wk High
$0.23
52-wk Low
$0.07

Summary

Name Age Since Current Position

Eric Adams

2016 President, Chief Executive Officer, Director

Terese Gieselman

2011 Chief Financial Officer

Chris Bogart

2016 Senior Vice President - Corporate Strategy and Investor Relations

Abo Mohammed

2015 Chief Medical Officer

Adam Cutler

2015 Director

William Garner

49 2016 Director

Craig Schneider

2015 Director

Biographies

Name Description

Eric Adams

Mr. Eric A. Adams is President, Chief Executive Officer, Director of the Company. Mr. Adams previously served as CEO at enGene Inc., which he led from a nascent start-up to becoming a venture capital-backed leader in gene therapy. Prior to enGene, he held key senior roles in global market development with QLT Inc. (Vancouver), Advanced Tissues Science Inc. (La Jolla), Abbott Laboratories (Chicago), and Fresenius AG (Germany). Mr. Adams is well regarded in the Canadian biotech industry for his service as a strategic advisor to a number of early-stage biotech companies, as a previous Chairman of BIOTECanada's Emerging Company Advisory Board and for his extensive generosity in mentoring biotech entrepreneurs. He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

Terese Gieselman

Ms. Terese J. Gieselman serves as Chief Financial Officer of Meridex Software Corp., since June 27, 2011. Ms. Gieselman has had 23 years experience with junior mining and exploration companies listed on the Toronto Stock Exchange, TSX Venture Exchange, OTCBB, the Nasdaq Stock Market and Amex in the roles of chief financial officer. Ms. Gieselman has accumulated an experience background in corporate and financial reporting and compliance for Canada and the United States, including particularly relevant experience in financings, treasury and international corporate structures.

Chris Bogart

Mr. Chris Bogart Senior Vice President - Corporate Strategy and Investor Relations of the Company. He served as Interim Chief Executive Officer of the Company.

Abo Mohammed

Dr. Abo Mohammed, M.D., DPM, MFPM, is Chief Medical Officer of the Company. Prior to joining InMed Pharmaceuticals, Dr. Mohammed served as associate medical director at GW Pharmaceuticals, a United Kingdom-based pharmaceutical company specializing in the development of cannabinoid-based prescription medicines. In this role, and others at GW Pharmaceuticals, Dr. Mohammed was involved in the advanced delivery of core clinical research, and was involved in key decision making regarding research and development, and product commercialization. He played a leading role in GW Pharmaceuticals' pharma-covigilance team, where his responsibilities included handling of the company's drug safety data from both clinical trials and postmarketing sources, and general management of safety signals including investigations, reviews and reporting. He is also a consultant to the Nigerian regulatory authority (National Agency for Food and Drug Administration and Control) in the areas of pharma-covigilance, postmarketing surveillance and clinical trials. Prior to joining GW Pharmaceuticals, Dr. Mohammed was with PPD (Pharmaceutical Product Development), a leading global contract research organization providing drug discovery, development, life cycle management and laboratory services. Dr. Mohammed also served as CMO/clinical director in various public health care establishments in Africa from 1996 to November, 2010. Dr. Mohammed received his MD at Ahmadu Bello University, Zaria, Nigeria, followed by an MSc in orthopedics at University College London. Dr. Mohammed achieved a DipPharMed in pharmaceutical medicine at the University of Wales in Cardiff. He is a member of the faculty of pharmaceutical medicine at the Royal College of Physicians of England, the British Association of Pharmaceutical Physicians and the International Society for Pharma-covigilance.

Adam Cutler

Mr. Adam D. Cutler is Director of InMed Pharmaceuticals Inc. Mr. Cutler is currently senior vice-president of corporate affairs at Arbutus Biopharma, and previously was a managing director at The Trout Group LLC and Trout Capital LLC, where he successfully executed financings and advised a wide range of life science companies on investor relations, business development and capital-raising strategy. Mr. Cutler spent almost 12 years as a sell-side analyst with firms including Credit Suisse, Canaccord Genuity, JMP Securities and Bank of America Securities, with prior analytical and consulting experience at The Frankel Group and Ernst & Young, health care consulting. Mr. Cutler holds a BA in economics from Brandeis University.

William Garner

Dr. William J. Garner, M.D. is Director of the Company. He is the founder of EGB Advisors PR LLC, a pharmaceutical commercialization boutique, where he has focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, mergers and acquisitions, or initial public offering transactions. Dr. Garner has extensive director-level and executive management experience, including his current appointment as chairman and founder of Update Pharma, and as a director at IGXBio. He has previously served as chief executive officer of Invion Ltd., a clinical-stage anti-inflammatory drug development company that resulted from the merger of a private company he founded, and as a co-founder and director of Del Mar Pharmaceuticals. Dr. Garner brings additional medical affairs experience from his tenure at Hoffmann LaRoche's oncology division. Prior to Roche, Dr. Garner was a health care merchant banker in New York. He has a master of public health from Harvard and earned his MD at New York Medical College. Dr. Garner did residency training in anatomic pathology at Columbia-Presbyterian and is currently a licensed physician in the state of New York.

Craig Schneider

Mr. Craig Schneider is Director of the Company., effective September 14, 2015. He was President, Chief Executive Officer of Meridex Software Corp., effective 10 December 2012.

Basic Compensation